Magnitude and Durability of the Antibody Response to mRNA-Based Vaccination Among SARS-CoV-2 Seronegative and Seropositive Health Care PersonnelOPEN FORUM INFECTIOUS DISEASESIF3.82024-01-192OAAI
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) StudyMBIOIF4.72022-10-267OAAI
Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020MSPHEREIF3.12022-06-294OAAI
Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort StudiesOPEN FORUM INFECTIOUS DISEASESIF3.82022-04-276OAAI
Encephalitis Caused by Jamestown Canyon Virus in a Liver Transplant Patient, North Carolina, USA, 2017OPEN FORUM INFECTIOUS DISEASESIF3.82022-01-303OAAI
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals (vol 6, e00275-21, 2021)MSPHEREIF3.12021-10-270OAAI
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent IndividualsMSPHEREIF3.12021-08-2538OAAI
A Novel Antigenic Site Spanning Domains I and III of the Zika Virus Envelope Glycoprotein Is the Target of Strongly Neutralizing Human Monoclonal AntibodiesJOURNAL OF VIROLOGYIF3.82021-04-123OAAI
The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsSCIENCE IMMUNOLOGYIF16.32020-06-26653OAAI
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivoScienceIF45.82020-01-010OAAI